title: Taurine ameliorates hyperglycemia and dyslipidemia by reducing insulin resistance and leptin level in Otsuka Long-Evans Tokushima fatty (OLETF) rats with long-term diabetes.
abstract: This study aimed to determine whether taurine supplementation improves metabolic disturbances and diabetic complications in an animal model for type 2 diabetes. We investigated whether taurine has therapeutic effects on glucose metabolism, lipid metabolism, and diabetic complications in Otsuka Long- Evans Tokushima fatty (OLETF) rats with long-term duration of diabetes. Fourteen 50-week-old OLETF rats with chronic diabetes were fed a diet supplemented with taurine (2%) or a non-supplemented control diet for 12 weeks. Taurine reduced blood glucose levels over 12 weeks, and improved OGTT outcomes at 6 weeks after taurine supplementation, in OLETF rats. Taurine significantly reduced insulin resistance but did not improve β-cell function or islet mass. After 12 weeks, taurine significantly decreased serum levels of lipids such as triglyceride, cholesterol, high density lipoprotein cholesterol, and low density lipoprotein cholesterol. Taurine significantly reduced serum leptin, but not adiponectin levels. However, taurine had no therapeutic effect on damaged tissues. Taurine ameliorated hyperglycemia and dyslipidemia, at least in part, by improving insulin sensitivity and leptin modulation in OLETF rats with long-term diabetes. Additional study is needed to investigate whether taurine has the same beneficial effects in human diabetic patients.
authors.affiliation: East-West Bone and Joint Research Institute, Kyung Hee University Hospital at Gangdong, Korea. labrea46@yahoo.co.kr
authors.forename: Kyoung Soo
authors.initials: KS
authors.lastname: Kim
authors.forename: Da Hee
authors.initials: DH
authors.lastname: Oh
authors.forename: Jung Yeon
authors.initials: JY
authors.lastname: Kim
authors.forename: Bong Gn
authors.initials: BG
authors.lastname: Lee
authors.forename: Jeong Soon
authors.initials: JS
authors.lastname: You
authors.forename: Kyung Ja
authors.initials: KJ
authors.lastname: Chang
authors.forename: Hyun Ju
authors.initials: HJ
authors.lastname: Chung
authors.forename: Myung Chul
authors.initials: MC
authors.lastname: Yoo
authors.forename: Hyung In
authors.initials: HI
authors.lastname: Yang
authors.forename: Ja Heon
authors.initials: JH
authors.lastname: Kang
authors.forename: Yoo Chul
authors.initials: YC
authors.lastname: Hwang
authors.forename: Kue Jeong
authors.initials: KJ
authors.lastname: Ahn
authors.forename: Ho Yeon
authors.initials: HY
authors.lastname: Chung
authors.forename: In Kyung
authors.initials: IK
authors.lastname: Jeong
mesh_terms: D054392:Adipokines / Q000097:blood; D000818:Animals; D001786:Blood Glucose; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D019587:Dietary Supplements; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy*; D005951:Glucose Tolerance Test; D006943:Hyperglycemia / Q000097:blood / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D007328:Insulin / Q000378:metabolism / Q000502:physiology; D007333:Insulin Resistance; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000378:metabolism / Q000502:physiology; D020738:Leptin / Q000097:blood*; D050356:Lipid Metabolism / Q000187:drug effects; D008055:Lipids / Q000097:blood; D008297:Male; D009928:Organ Specificity; D051381:Rats; D020318:Rats, Long-Evans; D013654:Taurine / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D054392:Adipokines; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D007328:Insulin; D020738:Leptin; D008055:Lipids; D013654:Taurine